Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis

Wenfei Wang; Noa Krugliak Cleveland; Jacob Ollech; David T Rubin

doi:10.14309/crj.0000000000000226

Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis

ACG Case Rep J. 2019 Sep 12;6(9):e00226. doi: 10.14309/crj.0000000000000226. eCollection 2019 Sep.

Authors

Wenfei Wang¹, Noa Krugliak Cleveland², Jacob Ollech², David T Rubin²

Affiliations

¹ Department of Medicine, University of Chicago Medicine, Chicago, IL.
² Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL.

Abstract

Tofacitinib is a Janus kinase 1-3 inhibitor initially approved for the treatment of rheumatoid arthritis and now approved for the treatment of moderately to severely active ulcerative colitis (UC). We present the case of a patient with UC and seronegative inflammatory arthritis in whom arthritis progressed while on vedolizumab and was successfully treated with tofacitinib. This case provides insight into the use of tofacitinib for the treatment of UC and a concomitant extraintestinal manifestation of joint involvement.

Publication types

Case Reports